Supplementary material

Bacharach J, Tatham A, Ferguson G, Belalcázar S, Thieme H, Goodkin ML, Chen MY, Guo Q, Liu J, Robinson MR, Bejanian M, Wirta DL; on behalf of the ARTEMIS 2 Study Group. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). *Drugs*.

Author for correspondence: Jason Bacharach, MD; North Bay Eye Associates, Petaluma, CA, USA; Email: jbacharach@northbayeye.com

Online Resource 4



Mean diurnal IOP in study eyes during the active treatment period (BL to W52) and the extended follow-up (M14 to M12). The analysis used observed values in eyes that had not been rescued. The number of eyes included in the analysis ranged from 113 to 176 in the 10-µg bimatoprost implant group, 110 to 176 in the 15-µg bimatoprost implant group, and 136 to 175 in the timolol BID group. The timing of implant or sham administration is shown with arrows. *BID* twice daily, *IOP* intraocular pressure, *SEM* standard error of the mean